The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures

Journal of Neuroinflammation

Volumn 13, Issue 1, 2016, Pages

  O'Sullivan, Catherine ^a   Schubart, Anna ^b   Mir, Anis K ^b   Dev, Kumlesh K ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Aastrocytes; Demyelination; Krabbe disease; Siponimod (BAF312); Sphingosine 1 phosphate receptors (S1PRs)

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LYSOPHOSPHATIDYLCHOLINE; MITOGEN ACTIVATED PROTEIN KINASE; MYELIN BASIC PROTEIN; PROTEIN KINASE B; PSYCHOSINE; SIPONIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; SPHINGOSINE 1 PHOSPHATE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 1-(4-(1-((E)-4-CYCLOHEXYL-3-TRIFLUOROMETHYLBENZYLOXYIMINO)-ETHYL)-2-ETHYLBENZYL)-AZETIDINE-3-CARBOXYLIC ACID; 2-(4-(5-(3,4-DIETHOXYPHENYL)-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL AMINO)ETHANOL; 3 [2 (3 TRIFLUOROMETHYL 4 BIPHENYLYL)BENZO[B]THIEN 5 YLMETHYLAMINO]PROPIONIC ACID; ANTIINFLAMMATORY AGENT; AZETIDINE DERIVATIVE; BENZYL DERIVATIVE; BETA ALANINE; EIF2AK3 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; INDAN DERIVATIVE; OXADIAZOLE DERIVATIVE; PROTEIN KINASE R; THIOPHENE DERIVATIVE;

ANIMAL CELL; ARTICLE; ASTROCYTE; CALCIUM SIGNALING; CELL FUNCTION; CEREBELLAR SLICE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DEMYELINATION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTERNALIZATION; MICROGLIA; MYELINATION; NEUROFILAMENT; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; WESTERN BLOTTING; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CEREBELLUM; CYTOLOGY; DEMYELINATING DISEASES; DRUG EFFECTS; GENETICS; IN VITRO STUDY; METABOLISM; MOUSE; NEWBORN; ORGAN CULTURE TECHNIQUE; PROTEIN TRANSPORT; TIME FACTOR;

ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS; ASTROCYTES; AZETIDINES; BENZYL COMPOUNDS; BETA-ALANINE; CALCIUM SIGNALING; CEREBELLUM; DEMYELINATING DISEASES; EIF-2 KINASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IN VITRO TECHNIQUES; INDANS; INTERLEUKIN-6; LYSOPHOSPHATIDYLCHOLINES; MICE; MYELIN BASIC PROTEIN; ORGAN CULTURE TECHNIQUES; OXADIAZOLES; PROTEIN TRANSPORT; RECEPTORS, LYSOSPHINGOLIPID; THIOPHENES; TIME FACTORS;

EID: 84958155181     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-016-0494-x     Document Type: Article

References (42)

1. Fyrst H, Saba JD. An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol. 2010;6(7):489-97.
2. Kappos L, Radue E-W, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
3. Adachi K, Chiba K, FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology. Perspect Medicin Chem. 2008;1:11-23.
4. Jackson SJ, Giovannoni G, Baker D. Fingolimod modulates microglial activation to augment markers of remyelination. J Neuroinflammation. 2011;8:76.
5. Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci. 2011;108(2):751-6.
6. Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G, Hoyer D, et al. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther. 2008;117(1):77-93.
7. Mattes H, Dev KK, Bouhelal R, Barske C, Gasparini F, Guerini D, et al. Design and synthesis of selective and potent orally active S1P5 agonists. ChemMedChem. 2010;5(10):1693-6.
8. Miron VE, Ludwin SK, Darlington PJ, Jarjour AA, Soliven B, Kennedy TE, et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol. 2010;176(6):2682-94.
9. Sheridan GK, Dev KK. S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures. Glia. 2012;60(3):382-92.
10. Pan S, Gray NS, Gao W, Mi Y, Fan Y, Wang X, et al. Discovery of BAF312 (Siponimod), a potent and selective S1P receptor modulator. ACS Med Chem Lett. 2013;4(3):333-7.
11. Chae SS, Proia RL, Hla T. Constitutive expression of the S1P1 receptor in adult tissues. Prostaglandins Other Lipid Mediat. 2004;73(1-2):141-50.
12. Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem. 2004;73(1):321-54.
13. Jaillard C, Harrison S, Stankoff B, Aigrot MS, Calver AR, Duddy G, et al. Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci. 2005;25(6):1459-69.
14. Im D-S, Heise CE, Ancellin N, O'Dowd BF, Shei G-J, Heavens RP, et al. Characterization of a novel sphingosine 1 phosphate receptor, Edg-8. J Biol Chem. 2000;275(19):14281-6.
15. Forrest M, Sun S-Y, Hajdu R, Bergstrom J, Card D, Doherty G, et al. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther. 2004;309(2):758-68.
16. Gergely P, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012;167(5):1035-47.
17. Legangneux E, Gardin A, Johns D. Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects. Br J Clin Pharmacol. 2013;75(3):831-41.
18. Selmaj K et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013;2(8):756-67.
19. Healy LM, Sheridan GK, Pritchard AJ, Rutkowska A, Mullershausen F, Dev KK. Pathway specific modulation of S1P1 receptor signalling in rat and human astrocytes. Br J Pharmacol. 2013;169(5):1114-29.
20. Rutkowska A, Preuss I, Gessier F, Sailer AW, Dev KK. EBI2 regulates intracellular signaling and migration in human astrocyte. Glia. 2015;63(2):341-51.
21. Pritchard AJ, Mir AK, Dev KK. Fingolimod attenuates splenocyte-induced demyelination in cerebellar slice cultures. PLoS One. 2014;9(6):e99444.
22. Mullershausen F et al. Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J Neurochem. 2007;102(4):1151-61.
23. Quancard J, Bollbuck B, Janser P, Angst D, Berst F, Buehlmayer P, et al. A potent and selective S1P1 antagonist with efficacy in experimental autoimmune encephalomyelitis. Chem Biol. 2012;19(9):1142-51.
24. Osinde M, Mullershausen F, Dev KK. Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. Neuropharmacology. 2007;52(5):1210-8.
25. Lee M-J et al. Akt-mediated phosphorylation of the G protein-coupled receptor EDG-1 is required for endothelial cell chemotaxis. Mol Cell. 2001;8(3):693-704.
26. Liu G, Burns S, Huang G, Boyd K, Proia RL, Flavell RA, et al. The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. Nat Immunol. 2009;10(7):769-77.
27. Parpura V, Verkhratsky A. Homeostatic function of astrocytes: Ca(2+) and Na(+) signalling. Transl Neurosci. 2012;3(4):334-44.
28. Wang W, Huang M-C, Goetzl EJ. Type 1 sphingosine 1-phosphate g protein-coupled receptor (S1P1) mediation of enhanced IL-4 generation by CD4 T cells from S1P1 transgenic mice. J Immunol. 2007;178(8):4885-90.
29. Zhang Z, Fauser U, Schluesener HJ. Early attenuation of lesional interleukin-16 up-regulation by dexamethasone and FTY720 in experimental traumatic brain injury. Neuropathol Appl Neurobiol. 2008;34(3):330-9.
30. Elain G et al. The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes. Glia. 2014;62(5):725-35.
31. Davenport, Williamson, and Taylor. Pathophysiology of Krabbe disease. Orbit: The University of Sydney undergraduate research journal. 2011;2(1):1-20.
32. O'Sullivan C, Dev KK. Galactosylsphingosine (psychosine) induced demyelination is attenuated by sphingosine 1-phosphate signalling. J Cell Sci. 2015;128(21):3878-87.
33. Coelho RP et al. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther. 2007;323(2):626-35.
34. Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP, et al. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol. 2008;63(1):61-71.
35. Jung CG, Kim HJ, Miron VE, Cook S, Kennedy TE, Foster CA, et al. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia. 2007;55(16):1656-67.
36. Yang L, Chang N, Liu X, Han Z, Zhu T, Li C, et al. Bone marrowderived mesenchymal stem cells differentiate to hepatic myofibroblasts by transforming growth factor-β1 via sphingosine kinase/sphingosine 1-phosphate (S1P)/S1P receptor axis. Am J Pathol. 2012;181(1):85-97.
37. Noda H, Takeuchi H, Mizuno T, Suzumura A. Fingolimod phosphate promotes the neuroprotective effects of microglia. J Neuroimmunol. 2013;256(1-2):13-8.
38. Prodinger C, Bunse J, Krüger M, Schiefenhövel F, Brandt C, Laman J, et al. CD11c-expressing cells reside in the juxtavascular parenchyma and extend processes into the glia limitans of the mouse nervous system. Acta Neuropathol. 2011;121(4):445-58.
39. Ling C, Verbny YI, Banks MI, Sandor M, Fabry Z. In situ activation of antigen-specific CD8+ T cells in the presence of antigen in organotypic brain slices. J Immunol. 2008;180(12):8393-9.
40. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002;296(5566):346-9.
41. Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, et al. P036-siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: design of the phase 3 EXPAND trial. Mult Scler Relat Disord. 2014;3(6):752.
42. Al-Izki S, Pryce G, Jackson SJ, Giovannoni G, Baker D. Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. Mult Scler J. 2011;17(8):939-48.